Nastech Pharmaceutical Company announced that it has received clearance from the U.S. Food and Drug Administration to market its non-invasive Mammary Aspiration Specimen Cytology Test (MASCT) device for the early detection of breast cancer.

The patented device helps doctors find atypical changes in cells lining the milk ducts, where an estimated 95 percent of all breast cancers begin.

A clinical trial of healthy, non-pregnant, non-lactating, pre-menopausal women, aged 30 to 49, showed that the MASCT device produces results that correlate with mammogram and clinical breast exam results. The MASCT device successfully collected diagnostic amounts of Nipple Aspirate Fluid for a conclusive cytological examination.

Other Sources: Nastech